Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

Upadacitinib at the FDA

Michele B. Kaufman, PharmD, BCGP  |  February 28, 2019

Upadacitinib is an investigational, oral, small molecule JAK1-selective inhibitor, which recently completed phase 3 clinical trials for treating patients with moderate to severe rheumatoid arthritis (RA). In late 2018, AbbVie Inc. submitted a New Drug Application to the U.S. Food and Drug Administration, as well as a marketing authorization application to the European Medicines Agency,…

Filed under:Drug Updates Tagged with:FDARheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)upadacitinib

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD  |  February 17, 2019

As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…

Filed under:Biologics/DMARDsResearch RheumRheumatoid ArthritisSpeak Out Rheum Tagged with:OpinionSpeak Out Rheumatology

RA Effectiveness Differs Among Non-TNF Inhibitors

Will Boggs, MD  |  February 5, 2019

NEW YORK (Reuters Health)—Rheumatoid arthritis (RA) outcomes are better with some non-TNF inhibitors than with others, according to French registry data. “Previously, indirect comparisons (meta-analyses) did not show any difference between biologics in terms of effectiveness,” Dr. Jacques-Eric Gottenberg from Strasbourg University Hospital, France, tells Reuters Health by email. “Our direct comparison using observational data…

Filed under:ConditionsRheumatoid Arthritis Tagged with:abataceptnon-TNF inhibitorsRheumatoid Arthritis (RA)rituximabtocilizumab

Rheumatoid Arthritis Prevention, Remission & Treatment De-Escalation

Thomas R. Collins  |  January 17, 2019

CHICAGO—With an ever-strengthening foundation beneath the pathophysiology and prediction of rheumatoid arthritis (RA), the field may soon focus more intently on prevention, an expert said at the 2018 ACR/ARHP Annual Meeting. The session also covered the latest in remission targets and therapy de-escalation. RA Prevention Kevin Deane, MD, PhD, associate professor of medicine and principal…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:2018 ACR/ARHP Annual MeetingpreventionRemissiontreatment de-escalation

Course of treatment over time

Case Report: The Hairdresser Who Couldn’t Comb Her Hair

Erin Hammett, DO, & Edward Skol, MD  |  November 19, 2018

Polymyalgia rheumatica (PMR) is an inflammatory rheumatic condition characterized by pain and morning stiffness at the neck, shoulders and hip girdle. It can be associated with giant cell arteritis (GCA); in fact, the two disorders may represent a continuum of the same disease process. This case describes a patient who initially refused treatment for PMR…

Filed under:ConditionsVasculitis Tagged with:abataceptcase reportGiant Cell ArteritislithiumMethotrexatePMR FocusRheumPolymyalgia RheumaticaSteroidstocilizumab

Uveitis: Know the Risk Factors, Symptoms & Treatment Options

Carina Stanton  |  October 22, 2018

Inflammatory diseases can cause uveitis. Early detection and treatment are essential, but when uveitis goes undetected it can cause blindness. Here’s how to protect your patients…

Filed under:Conditions Tagged with:eyeEye diseaseUveitisvision

Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection

Thomas R. Collins  |  September 20, 2018

AMSTERDAM—With new therapies coming into the marketplace, researchers are working to tease out the risk of infection for rheumatoid arthritis (RA) patients. Existing data suggest the risk of infections—even fatal ones—is real. But over time, improvements have taken hold, particularly for tuberculosis, according to an infectious disease expert at EULAR: the Annual European Congress of…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:InfectionTuberculosis

Trial Data Reveals the Limitations of Steroids in Giant Cell Arteritis Therapy

Thomas R. Collins  |  September 20, 2018

AMSTERDAM—Just how seldom prednisone is successful at inducing remission in giant cell arteritis (GCA), despite such a long history of use for the disease, is one of the many lessons to emerge from the data in the GiACTA trial, said the principal investigator of the trial, which is the largest ever in GCA and is…

Filed under:ConditionsVasculitis Tagged with:giant cell arteritis (GCA)Steroidstocilizumab

Investigators Assess Infection Risk with RA Biologics

Thomas R. Collins  |  August 29, 2018

Due to a range of factors, determining the precise infection risk posed by new biologic therapies to RA patients is difficult. But progress has been made and health registries may be helpful, said Olivier Lortholary, MD, PhD, during the 2018 EULAR: Annual European Congress of Rheumatology…

Filed under:Biologics/DMARDsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:biologic drugsEULARInfectionRheumatoid Arthritis (RA)

Psoriatic Arthritis Research Continues Hunt for Biomarkers

Thomas R. Collins  |  August 17, 2018

AMSTERDAM—Molecular signatures in synovial tissue that can be gathered through biopsies are a largely untapped resource that could help guide treatment for rheumatic conditions, an expert said at the EULAR: Annual European Congress of Rheumatology. “I’m convinced that looking into synovial tissue provides us with tools to not only understand mechanisms of disease in rheumatoid…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:BiomarkersC-reactive protein (CRP)PsAsynovial biopsies

  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences